REN-1189 | CAS# 183619-38-7 | TNF-a release inhibitor

REN-1189
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530215

CAS#: 183619-38-7

Description: REN-1189 is a TNF-a release inhibitor potentially for the treatment of sciatica and postherpetic neuralgia.

Chemical Structure

REN-1189

CAS# 183619-38-7

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 530215
Name: REN-1189
CAS#: 183619-38-7
Chemical Formula: C13H18N2O2
Exact Mass: 234.14
Molecular Weight: 234.300
Elemental Analysis: C, 66.64; H, 7.74; N, 11.96; O, 13.66

Price and Availability

Size	Price	Availability	Quantity
500mg	USD -1
1g	USD -1
2g	USD -1
5g	USD -1
100mg	USD 350
250mg	USD 550
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: CPI-1189; REN-1189; REN-1654; CPI1189; REN1189; REN1654; CPI 1189; REN 1189; REN 1654

IUPAC/Chemical Name: 4-acetamido-N-(tert-butyl)benzamide

InChi Key: DJKNRCWSXSZACF-UHFFFAOYSA-N

InChi Code: InChI=1S/C13H18N2O2/c1-9(16)14-11-7-5-10(6-8-11)12(17)15-13(2,3)4/h5-8H,1-4H3,(H,14,16)(H,15,17)

SMILES Code: O=C(NC(C)(C)C)C1=CC=C(NC(C)=O)C=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:

Product Data

Instruction:

View handling instruction

Biological target:	REN-1189 can inhibit the activation of p38 mitogen activated protein kinase phosphorylation, and play a neuroprotective role.
In vitro activity:	REN-1189 alleviated oxygen glucose deprivation/re-oxygenation (OGDR)-induced programmed necrosis by inhibiting mitochondrial p53-cyclophilin D-adenine nucleotide translocase 1 association, mitochondrial depolarization, and lactate dehydrogenase release to the medium. REN-1189 potently inhibited OGDR-induced oxidative injury and neuronal cell death. Reference: Aging (Albany NY). 2021 Feb 17;13(5):6712-6723. https://pubmed.ncbi.nlm.nih.gov/33621193/
In vivo activity:	In this paper, REN-1189 is shown to mitigate apoptosis induced by TNFa, gp120, and necrosis induced by quinolinic acid. REN-1189 mitigates the cell death produced by supernatants from cultured macrophages obtained from patients with AIDS dementia. These findings may have implications for other neurological diseases where apoptotic cell death contributes to neurodegeneration. Reference: Brain Res. 2001 Mar 2;893(1-2):95-103. https://pubmed.ncbi.nlm.nih.gov/11222997/

Solubility Data

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
	DMSO	47.0	200.61
	Ethanol	15.0	64.02

Preparing Stock Solutions

The following data is based on the product molecular weight 234.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	1. Li YJ, Zhan Y, Li C, Sun J, Yang C. CPI-1189 protects neuronal cells from oxygen glucose deprivation/re-oxygenation-induced oxidative injury and cell death. Aging (Albany NY). 2021 Feb 17;13(5):6712-6723. doi: 10.18632/aging.202528. Epub 2021 Feb 17. PMID: 33621193; PMCID: PMC7993696. 2. Hensley K, Robinson KA, Pye QN, Floyd RA, Cheng I, Garland WA, Irwin I. CPI-1189 inhibits interleukin 1beta-induced p38-mitogen-activated protein kinase phosphorylation: an explanation for its neuroprotective properties? Neurosci Lett. 2000 Mar 10;281(2-3):179-82. doi: 10.1016/s0304-3940(00)00861-2. PMID: 10704772. 3. Pulliam L, Irwin I, Kusdra L, Rempel H, Flitter WD, Garland WA. CPI-1189 attenuates effects of suspected neurotoxins associated with AIDS dementia: a possible role for ERK activation. Brain Res. 2001 Mar 2;893(1-2):95-103. doi: 10.1016/s0006-8993(00)03293-5. PMID: 11222997. 4. Bjugstad KB, Flitter WD, Garland WA, Philpot RM, Kirstein CL, Arendash GW. CPI-1189 prevents apoptosis and reduces glial fibrillary acidic protein immunostaining in a TNF-alpha infusion model for AIDS dementia complex. J Neurovirol. 2000 Dec;6(6):478-91. doi: 10.3109/13550280009091948. PMID: 11175320.
In vitro protocol:	1. Li YJ, Zhan Y, Li C, Sun J, Yang C. CPI-1189 protects neuronal cells from oxygen glucose deprivation/re-oxygenation-induced oxidative injury and cell death. Aging (Albany NY). 2021 Feb 17;13(5):6712-6723. doi: 10.18632/aging.202528. Epub 2021 Feb 17. PMID: 33621193; PMCID: PMC7993696. 2. Hensley K, Robinson KA, Pye QN, Floyd RA, Cheng I, Garland WA, Irwin I. CPI-1189 inhibits interleukin 1beta-induced p38-mitogen-activated protein kinase phosphorylation: an explanation for its neuroprotective properties? Neurosci Lett. 2000 Mar 10;281(2-3):179-82. doi: 10.1016/s0304-3940(00)00861-2. PMID: 10704772.
In vivo protocol:	1. Pulliam L, Irwin I, Kusdra L, Rempel H, Flitter WD, Garland WA. CPI-1189 attenuates effects of suspected neurotoxins associated with AIDS dementia: a possible role for ERK activation. Brain Res. 2001 Mar 2;893(1-2):95-103. doi: 10.1016/s0006-8993(00)03293-5. PMID: 11222997. 2. Bjugstad KB, Flitter WD, Garland WA, Philpot RM, Kirstein CL, Arendash GW. CPI-1189 prevents apoptosis and reduces glial fibrillary acidic protein immunostaining in a TNF-alpha infusion model for AIDS dementia complex. J Neurovirol. 2000 Dec;6(6):478-91. doi: 10.3109/13550280009091948. PMID: 11175320.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Müller T. CPI-1189. Centaur. Curr Opin Investig Drugs. 2002 Dec;3(12):1763-7. Review. PubMed PMID: 12528314.

2: Clifford DB, McArthur JC, Schifitto G, Kieburtz K, McDermott MP, Letendre S, Cohen BA, Marder K, Ellis RJ, Marra CM; Neurologic AIDS Research Consortium.. A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. Neurology. 2002 Nov 26;59(10):1568-73. PubMed PMID: 12451199.

3: Bjugstad KB, Flitter WD, Garland WA, Philpot RM, Kirstein CL, Arendash GW. CPI-1189 prevents apoptosis and reduces glial fibrillary acidic protein immunostaining in a TNF-alpha infusion model for AIDS dementia complex. J Neurovirol. 2000 Dec;6(6):478-91. PubMed PMID: 11175320.

4: Pulliam L, Irwin I, Kusdra L, Rempel H, Flitter WD, Garland WA. CPI-1189 attenuates effects of suspected neurotoxins associated with AIDS dementia: a possible role for ERK activation. Brain Res. 2001 Mar 2;893(1-2):95-103. PubMed PMID: 11222997.

5: Hensley K, Robinson KA, Pye QN, Floyd RA, Cheng I, Garland WA, Irwin I. CPI-1189 inhibits interleukin 1beta-induced p38-mitogen-activated protein kinase phosphorylation: an explanation for its neuroprotective properties? Neurosci Lett. 2000 Mar 10;281(2-3):179-82. PubMed PMID: 10704772.

6: Bayes M, Rabasseda X, Prous JR. Gateways to Clinical Trials. June 2002. Methods Find Exp Clin Pharmacol. 2002 Jun;24(5):291-327. Review. PubMed PMID: 12168506.

7: Bjugstad KB, Flitter WD, Garland WA, Su GC, Arendash GW. Preventive actions of a synthetic antioxidant in a novel animal model of AIDS dementia. Brain Res. 1998 Jun 8;795(1-2):349-57. PubMed PMID: 9622673.

Your view history

REN-1189 featured